HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Robert Ings Selected Research

RP5063

10/2018A Population Pharmacokinetic and Pharmacodynamic Analysis of RP5063 Phase 2 Study Data in Patients with Schizophrenia or Schizoaffective Disorder.
1/2018Initial Clinical Experience of RP5063 Following Single Doses in Normal Healthy Volunteers and Multiple Doses in Patients with Stable Schizophrenia.
11/2017Dopamine serotonin stabilizer RP5063: A randomized, double-blind, placebo-controlled multicenter trial of safety and efficacy in exacerbation of schizophrenia or schizoaffective disorder.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Robert Ings Research Topics

Disease

3Schizophrenia (Dementia Praecox)
10/2018 - 11/2017
2Psychotic Disorders (Schizoaffective Disorder)
10/2018 - 11/2017
1Orthostatic Hypotension (Postural Hypotension)
11/2017
1Sleep Initiation and Maintenance Disorders (Insomnia)
11/2017
1Body Weight (Weight, Body)
11/2017

Drug/Important Bio-Agent (IBA)

3RP5063IBA
10/2018 - 11/2017
1Dopamine (Intropin)FDA LinkGeneric
11/2017
1LipidsIBA
11/2017
1ProlactinIBA
11/2017
1Serotonin (5 Hydroxytryptamine)IBA
11/2017
1Blood Glucose (Blood Sugar)IBA
11/2017